Qualified Polymer Feedstock · XETRA: EVK
Evonik: a pioneer in PA12 and high-performance polymer feedstock whose additive exposure remains financially hidden inside a global specialty-chemicals group.
Evonik’s INFINAM portfolio spans nylon powders, PEEK filaments, photopolymers and specialty materials for powder-bed fusion, extrusion and resin systems. The bottleneck is consistent chemistry, powder morphology, recyclability, process qualification and application support—not printer ownership.
As of: 18 July 2026 · Profile: Advanced polymer materials · Recommendation: None
Investor read
Evonik raised its 2026 earnings outlook sharply after a better-than-expected second quarter, but the improvement is not an additive-manufacturing signal. Preliminary Q2 adjusted EBITDA is expected between €600 million and €650 million, taking first-half adjusted EBITDA to roughly €1.1 billion. Full-year guidance increased to €2.0–€2.2 billion.
The uplift reflects higher volumes, pricing, cost savings and supply-chain shortages affecting Asian competitors, particularly in Advanced Technologies. Animal Nutrition also contributed. These drivers may normalize as global logistics recover.
Evonik’s AM relevance is nevertheless real and differentiated. It introduced polymer powder for SLS in 1996 and now offers PA12, PEEK, bio-circular and application-specific materials under INFINAM. The investment limitation is that AM revenue, margins, capacity and growth are not separately disclosed.
High-signal metrics
| Metric | Period | Investor interpretation |
|---|---|---|
| €600–650M adjusted EBITDA | Preliminary Q2 2026 | Midpoint approximately 23% above Q2 2025. |
| ~€1.1B adjusted EBITDA | H1 2026 preliminary | Supports a material upward revision to full-year guidance. |
| €2.0–2.2B adjusted EBITDA outlook | FY2026 | Raised from €1.7–2.0B. |
| €3.43B sales | Q1 2026 | Down 9%; more than half of decline from currency. |
| €475M adjusted EBITDA | Q1 2026 | Slightly above expectations despite weak demand. |
| €183M free cash flow | Q1 2026 | Near prior-year level. |
| ~40% cash-conversion target | FY2026 | Key test of earnings quality and leverage reduction. |
Business model
| Layer | Capability | Economic role |
|---|---|---|
| Specialty chemicals | Additives, nutrition, health-care and performance materials | Primary earnings base and capital-allocation engine. |
| High Performance Polymers | PA12, PEEK and specialty polymer chemistry | Provides differentiated raw materials for demanding applications. |
| INFINAM powders | PA12 and tailored powder-bed-fusion materials | Supports functional end-use polymer parts and recurring feedstock demand. |
| INFINAM filaments | High-temperature PEEK and industrial extrusion materials | Targets aerospace, medical and industrial performance requirements. |
| Photopolymers | Resins for vat-photopolymerization platforms | Expands exposure beyond powder-bed processes. |
| Application development | Material formulation, qualification and partner programs | Converts chemistry into printable, repeatable applications. |
| Circular solutions | Bio-circular feedstock and improved powder reuse | Addresses cost, waste and sustainability constraints. |
Why Evonik controls a polymer-feedstock bottleneck
- Long process history: Evonik has supplied polymer powder for additive manufacturing since 1996.
- PA12 expertise: chemistry, polymerization, particle production and application knowledge create qualification barriers.
- Powder consistency: particle size, shape, flowability, thermal window and refresh ratio influence every build.
- High-performance portfolio: PEEK, PA12 and specialty formulations address heat, chemical and mechanical requirements.
- Cross-platform reach: powders, filaments and resins diversify exposure across AM processes.
- Qualification support: material parameters and partnerships reduce development time for machine makers and users.
- Circularity capability: bio-circular raw materials and powder reuse can improve lifecycle economics.
Financial materiality
Emerging: AM can influence a business line or the strategic thesis, but is not yet dominant.
Addithive scorecard
| Dimension | Assessment | Rationale |
|---|---|---|
| Pure-play | 1 / 5 | AM is a small capability inside a diversified company. |
| Bottleneck ownership | 4 / 5 | Qualified or serial capability with meaningful switching costs, while viable alternatives remain. |
| Evidence maturity | Qualified | Qualified workflows or customer adoption are visible, but broad serial scale remains limited. |
| Financial materiality | Emerging | AM can influence a business line or the strategic thesis, but is not yet dominant. |
| Substitutability | Medium | Alternatives exist, but replacement requires workflow changes, requalification or integration effort. |
| Evidence confidence | High for cited operational evidence; lower for AM economics | Product, qualification and production claims are source-backed; AM-specific revenue and margin disclosure is often limited. |
Catalysts and thesis breakers
Catalysts
- Production polymer AM increasing powder consumption.
- Bio-circular PA12 winning regulated and sustainability-focused programs.
- PEEK and specialty materials moving into aerospace or medical production.
- Machine partnerships expanding qualified material channels.
- 2026 EBITDA landing near the top of raised guidance.
- Cash conversion improving and leverage declining.
- Evonik disclosing innovation-growth-field revenue.
Thesis breakers
- AM materials remaining permanently too small to affect earnings.
- Asian or integrated printer-material suppliers compressing margins.
- Open-material ecosystems commoditizing PA12.
- Supply-chain benefits reversing in the second half.
- Weak industrial demand offsetting cost savings.
- Restructuring costs and job cuts damaging innovation execution.
- Powder reuse and recycled alternatives reducing virgin-material demand.
Valuation context
Evonik should be valued on adjusted EBITDA durability, portfolio mix, cash conversion, leverage, restructuring execution, energy and raw-material exposure and the sustainability of pricing. Preliminary Q2 strength may include temporary scarcity economics.
AM materials add a high-quality innovation option but do not justify a separate valuation premium without disclosed revenue growth, production volumes or margins. The rerating evidence would be recurring feedstock growth from serial applications and measurable contribution to the High Performance Polymers business.
What to monitor
- Final Q2 2026 report on 4 August.
- Adjusted EBITDA and cash conversion versus raised guidance.
- Advanced Technologies pricing and supply normalization.
- INFINAM product launches and qualified machine partnerships.
- PA12 powder volumes, capacity and circular-material adoption.
- High-performance PEEK and medical-material programs.
- Tailor Made savings, restructuring costs and leverage.
Evidence gaps
- AM revenue, volume, margin, capacity and market share are not disclosed.
- INFINAM contribution within High Performance Polymers is unavailable.
- Machine-specific qualification economics and customer concentration are unknown.
- Virgin versus recycled powder mix is not reported.
- Current consensus, ownership and AM-specific capital employed were not sourced.
Source ledger
- Evonik preliminary Q2 2026 results — adjusted EBITDA, first-half performance and raised outlook.
- Evonik Q1 2026 results — sales, EBITDA, free cash flow and operating conditions.
- Tailor Made extension — restructuring and cost-reduction measures.
- INFINAM portfolio — polymer AM material range.
- INFINAM technologies — process history and platform coverage.
- Evonik polymer powders — PA12, PEEK and specialty material applications.
- Evonik investor relations — current reporting and event schedule.
Research conclusion
Evonik is a genuine polymer-AM bottleneck owner, but not a direct additive-manufacturing earnings vehicle.
Its decades of PA12 experience, qualified materials and high-performance polymer portfolio matter to production adoption. The stock is driven by specialty-chemicals demand, pricing, restructuring, cash conversion and leverage. AM becomes investable as a distinct thesis only when feedstock volumes and financial contribution are disclosed or visible through sustained segment outperformance.
Research use only. This page is not investment advice.
Return to the Public Additive Manufacturing Companies Directory →